BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chin RI, Wu FS, Menda Y, Kim H. Radiopharmaceuticals for Neuroendocrine Tumors. Semin Radiat Oncol 2021;31:60-70. [PMID: 33246637 DOI: 10.1016/j.semradonc.2020.07.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Prado-Wohlwend S, Bernal-Vergara JC, Utrera-Costero A, Cañón-Sánchez JR, Agudelo-Cifuentes M, Bello-Arques P; Endocrinology Working Group of the SEMNIM. Peptide receptor radionuclide therapy with [177Lu]Lu-DOTA-TATE. Rev Esp Med Nucl Imagen Mol (Engl Ed) 2021:S2253-8089(21)00164-6. [PMID: 34920969 DOI: 10.1016/j.remnie.2021.11.001] [Reference Citation Analysis]
2 Artigas C, Mileva M, Flamen P, Karfis I. Targeted radionuclide therapy: an emerging field in solid tumours. Curr Opin Oncol 2021;33:493-9. [PMID: 34183491 DOI: 10.1097/CCO.0000000000000762] [Reference Citation Analysis]
3 Kiess AP, Hobbs RF, Bednarz B, Knox SJ, Meredith R, Escorcia FE. ASTRO's Framework for Radiopharmaceutical Therapy Curriculum Development for Trainees. Int J Radiat Oncol Biol Phys 2022;113:719-26. [PMID: 35367328 DOI: 10.1016/j.ijrobp.2022.03.018] [Reference Citation Analysis]
4 Rogoza O, Megnis K, Kudrjavceva M, Gerina-Berzina A, Rovite V. Role of Somatostatin Signalling in Neuroendocrine Tumours. Int J Mol Sci 2022;23:1447. [PMID: 35163374 DOI: 10.3390/ijms23031447] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Yozgat A, Kekilli M, Altay M. Time to give up traditional methods for the management of gastrointestinal neuroendocrine tumours. World J Clin Cases 2021; 9(29): 8627-8646 [PMID: 34734042 DOI: 10.12998/wjcc.v9.i29.8627] [Reference Citation Analysis]